References
- Bruckner H W, Kalnicki S, Dalton J, et al. Survival after combined modality therapy for pancreatic cancer. J Clin Gastroenterol 1993; 16: 199–203
- Gattani A, Mandeli J, Chesser M R, Bruckner H W. An active biochemical modulation regimen for advanced pancreatic cancer (Abstract). Proc Am Soc Clin Oncol 1992; 11: 193
- Bruckner H W, Kalnicki S, Dalton J, et al. Combined modality therapy increasing local control of pancreatic cancer. Cancer Invest 1993; 11: 241–6
- Langstein H N, Norton J A, Chiang V, et al. The utility of circulating levels of human pancreatic polypeptide as a marker for islet cell tumors. Surgery 1990; 108: 1109–16
- Adrian T E, Uttenthal L O, Phil D, Williams S J, Blom S R. Secretion of pancreatic polypeptide in patients with pancreatic endocrine tumors. N Engl J Med 1986; 315: 287–91
- Norton J A, Fraker D L. Malignant neoplasms: the role of specific serum tests in the diagnosis, management and evaluation of recurrence. Textbook of surgery update. 2nd ed, D C Sabiston, Jr. WB Saunders, Philadelphia 1989; 19–37
- Theodorsson E. Regulatory peptides as tumor markers. Acta Oncol 1989; 28: 319–24
- Bruckner H W, Chesser M R, Mandeli J, Farber L, DiGiovanni J, Blenman C. Presence of polypeptide endocrine tumor markers in patients with localized and metastatic apparent adenocarcinoma of the pancreas and bile ducts (Abstract). Proc Am Assoc Cancer Res 1992; 33: 238
- Kimura W, Kuroda A, Morioka Y. Clinical pathology of endocrine tumors of the pancreas. Dig Dis Sci 1991; 36: 933–42
- Permert J, Mogaki M, Andren-Sandberg A, Kazakoff K, Pour P M. Pancreatic mixed ductal-islet tumors. Is this an entity?. Int J Pancreatol 1992; II: 23–9